Search
Nitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895] … [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.
Synonyms: N-(5-Nitrofurfurylidene)-1-aminohydantoinGinkgolide A
go.drugbank.com/drugs/DB06743ExperimentalNutraceuticalShows potential in a wide variety of inflammatory and immunological disorders.
TBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.
Entolimod
go.drugbank.com/drugs/DB12304InvestigationalEntolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among
ST-101
go.drugbank.com/drugs/DB12621InvestigationalST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.[A260411]
Gestaclone
go.drugbank.com/drugs/DB21090ExperimentalThe usage of the INN stem '-clone' in the name indicates that Gestaclone is a hypnotic tranquillizer. Gestaclone has a monoisotopic molecular weight of 370.17 Da.
Pinolcaine
go.drugbank.com/drugs/DB21159ExperimentalThe usage of the INN stem '-caine' in the name indicates that Pinolcaine is a local anaesthetic. Pinolcaine has a monoisotopic molecular weight of 351.22 Da.
Prazepine
go.drugbank.com/drugs/DB20174ExperimentalThe usage of the INN stem '-zepine' in the name indicates that Prazepine is a tricyclic compound. Prazepine has a monoisotopic molecular weight of 280.19 Da.
Fexicaine
go.drugbank.com/drugs/DB20038ExperimentalThe usage of the INN stem '-caine' in the name indicates that Fexicaine is a local anaesthetic. Fexicaine has a monoisotopic molecular weight of 426.25 Da.
Cyclo(prolylglycyl)
go.drugbank.com/drugs/DB04541InvestigationalNA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy